OXavidin for tissue targeting biotinylated therapeutics

Rita De Santis, Claudio Albertoni, Antonio Rosi, Barbara Leoni, Fiorella Petronzelli, Valeria D'Alessio, Eleonora Nucera, Giovanni Salvatori, Giovanni Paganelli, Antonio Verdoliva, Paolo Carminati, Carlo Antonio Nuzzolo

Research output: Contribution to journalArticlepeer-review


Avidin is a glycoprotein from hen egg white that binds biotin with very high affinity. Here we describe OXavidin, a product containing aldehyde groups, obtained by ligand-assisted sugar oxidation of avidin by sodium periodate. OXavidin chemically reacts with cellular and tissue proteins through Schiff's base formation thus residing in tissues for weeks while preserving the biotin binding capacity. The long tissue residence of OXavidin as well as that of OXavidin/biotinylated agent complex occurs in normal and neoplastic tissues and immunohistochemistry shows a strong and homogenous stromal localization. Once localized in tissue/tumor, OXavidin becomes an artificial receptor for intravenous injected biotin allowing tumor targeting with biotinylated therapeutics like radioisotopes or toxins. Moreover, present data also suggest that OXavidin might be useful for the homing of biotinylated cells. Overall, OXavidin exhibits a remarkable potential for many different therapeutic applications.

Original languageEnglish
Article number921434
JournalJournal of Biomedicine and Biotechnology
Publication statusPublished - 2009

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Medicine
  • Genetics
  • Molecular Biology
  • Health, Toxicology and Mutagenesis
  • Medicine(all)


Dive into the research topics of 'OXavidin for tissue targeting biotinylated therapeutics'. Together they form a unique fingerprint.

Cite this